000			04699nam a22006857a 4500
008			232233s20232023 xxu||||| |||| 00| 0 eng d
022			_a1936-8798
024			_a10.1016/j.jcin.2023.06.041 [doi]
024			_aS1936-8798(23)01038-5 [pii]
040			_aOvid MEDLINE(R)
099			_a37758379
245			_a5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results.
251			_aJacc: Cardiovascular Interventions. 16(18):2211-2227, 2023 09 25.
252			_aJACC Cardiovasc Interv. 16(18):2211-2227, 2023 09 25.
253			_aJACC. Cardiovascular interventions
260			_c2023
260			_fFY2024
260			_p2023 09 25
265			_sppublish
265			_tMEDLINE
266			_d2023-11-22
520			_aBACKGROUND: The MITRAL (Mitral Implantation of Transcatheter Valves) trial is the first prospective trial to evaluate the safety and feasibility of balloon-expandable aortic transcatheter heart valves in patients with failed surgical bioprostheses or annuloplasty rings and severe mitral annular calcification treated with mitral valve-in-valve (MViV), valve-in-ring (MViR), or valve-in-mitral annular calcification (ViMAC).
520			_aCONCLUSIONS: MViV, MViR, and ViMAC procedures were associated with sustained improvement of heart failure symptoms and quality of life among survivors at 5 years. Transcatheter heart valve function remained stable in all 3 groups. Patients treated with MViV had excellent survival at 5 years, whereas survival was lower in the MViR and ViMAC groups, consistent with underlying disease severity. Patients with more residual mitral regurgitation had higher mortality. Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
520			_aMETHODS: A multicenter prospective study was conducted among patients at high surgical risk at 13 U.S. sites. Patients underwent MViV (n = 30), MViR (n = 30), or ViMAC (n = 31) and were followed annually for 5 years. Kansas City Cardiomyopathy Questionnaire scores were obtained at baseline and follow-up visits. Echocardiograms were analyzed at independent core laboratories.
520			_aOBJECTIVES: The aim of this study was to evaluate 5-year outcomes among these patients.
520			_aRESULTS: A total of 91 patients underwent transcatheter mitral valve replacement (February 2015 to December 2017). The mean age was 74.3 +/- 8.9 years. At 5-year follow-up, the lowest all-cause mortality was observed in the MViV group (21.4%), 94.7% of patients were in NYHA functional class I or II, and the mean mitral gradient was 6.6 +/- 2.5 mm Hg. The MViR and ViMAC groups had higher all-cause mortality (65.5% and 67.9%), most survivors were in NYHA functional classes I and II (50% and 55.6%), and mean mitral gradients remained stable (5.8 +/- 0.1 and 6.7 +/- 2.5 mm Hg). Significant improvements in Kansas City Cardiomyopathy Questionnaire scores were observed when all 3 arms were pooled.
546			_aEnglish
650			_a*Calcinosis
650			_a*Cardiomyopathies
650			_a*Heart Valve Diseases
650			_a*Heart Valve Prosthesis
650			_a*Heart Valve Prosthesis Implantation
650			_a*Mitral Valve Insufficiency
650			_a*Vascular Diseases
650			_aAged
650			_aAged, 80 and over
650			_aCalcinosis/su [Surgery]
650			_aCardiac Catheterization/mt [Methods]
650			_aHeart Valve Diseases/dg [Diagnostic Imaging]
650			_aHeart Valve Diseases/su [Surgery]
650			_aHumans
650			_aMitral Valve Insufficiency/dg [Diagnostic Imaging]
650			_aMitral Valve Insufficiency/et [Etiology]
650			_aMitral Valve Insufficiency/su [Surgery]
650			_aMitral Valve/dg [Diagnostic Imaging]
650			_aMitral Valve/su [Surgery]
650			_aProspective Studies
650			_aQuality of Life
650			_aTreatment Outcome
650			_aVascular Diseases/et [Etiology]
650			_zAutomated
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
657			_aMulticenter Study
657			_aResearch Support, Non-U.S. Gov't
700			_aSatler, Lowell F _bMHVI
790			_aGuerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, Palacios I, Russell H, Makkar RR, Kar S, Satler LF, Rajagopal V, Dangas G, Tang GHL, McCabe JM, Whisenant BK, Fang K, Balan P, Smalling R, Kaptzan T, Lewis B, Douglas PS, Hahn RT, Thaden J, Oh JK, Leon M, O'Neill W, Rihal C
856			_uhttps://dx.doi.org/10.1016/j.jcin.2023.06.041 _zhttps://dx.doi.org/10.1016/j.jcin.2023.06.041
942			_cART _bArticle
999			_c13520 _d13520